Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury

Profyris, C. et al. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis. 15, 415–436 (2004). 10.1016/j.nbd.2003.11.015

[2]

Pardridge, W. M. Non-invasive drug delivery to the human brain using endogenous blood–brain barrier transport systems. Pharm. Sci. Technol. Today 2, 49–59 (1999). 10.1016/s1461-5347(98)00117-5

[3]

Palmer, A. M. & Alavijeh, M. S. Translational CNS medicines research. Drug. Discov. Today 17, 1068–1078 (2012). 10.1016/j.drudis.2012.05.001

[4]

Pangalos, M. N., Schechter, L. E. & Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature Rev. Drug Discov. 6, 521–532 (2007). 10.1038/nrd2094

[5]

Zhang, L., Zhang, Z. G. & Chopp, M. The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol. Sci. 33, 415–422 (2012). 10.1016/j.tips.2012.04.006

[6]

Andrieux, K. & Couvreur, P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood–brain barrier. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 463–474 (2009). 10.1002/wnan.5

[7]

Nair, S. B., Dileep, A. & Rajanikant, G. K. Nanotechnology based diagnostic and therapeutic strategies for neuroscience with special emphasis on ischemic stroke. Curr. Med. Chem. 19, 744–756 (2012). 10.2174/092986712798992138

[8]

Sun, Q., Radosz, M. & Shen, Y. Challenges in design of translational nanocarriers. J. Control Rel. 164, 156–169 (2012). 10.1016/j.jconrel.2012.05.042

[9]

Yang, H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 27, 1759–1771 (2010). 10.1007/s11095-010-0141-7

[10]

Boison, D. Adenosine as a neuromodulator in neurological diseases. Curr. Opin. Pharmacol. 8, 2–7 (2008). 10.1016/j.coph.2007.09.002

[11]

De Mendonca, A., Sebastiao, A. M. & Ribeiro, J. A. Adenosine: does it have a neuroprotective role after all? Brain Res. Rev. 33, 258–274 (2000). 10.1016/s0165-0173(00)00033-3

[12]

Williams-Karnesky, R. L. & Stenzel-Poore, M. P. Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. Curr. Neuropharmacol. 7, 217–227 (2009). 10.2174/157015909789152209

[13]

Fredholm, B. B., Chen, J. F., Cunha, R. A., Svenningsson, P. & Vaugeois, J. M. Adenosine and brain function. Int. Rev. Neurobiol. 63, 191–270 (2005). 10.1016/s0074-7742(05)63007-3

[14]

Gomes, C. V., Kaster, M. P., Tome, A. R., Agostinho, P. M. & Cunha, R. A. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim. Biophys. Acta 1808, 1380–1399 (2011). 10.1016/j.bbamem.2010.12.001

[15]

Moser, G. H., Schrader, J. & Deussen, A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 256, C799–C806 (1989). 10.1152/ajpcell.1989.256.4.c799

[16]

Cerqueira, M. D., Verani, M. S., Schwaiger, M., Heo, J. & Iskandrian, A. S. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J. Am. Coll. Cardiol. 23, 384–389 (1994). 10.1016/0735-1097(94)90424-3

[17]

Levine, A. S. & Morley, J. E. Purinergic regulation of food intake. Science 217, 77–79 (1982). 10.1126/science.7046046

[18]

Basheer, R., Strecker, R. E., Thakkar, M. M. & McCarley, R. W. Adenosine and sleep–wake regulation. Prog. Neurobiol. 73, 379–396 (2004). 10.1016/j.pneurobio.2004.06.004

[19]

Pardridge, W. M., Yoshikawa, T., Kang, Y. S. & Miller, L. P. Blood–brain barrier transport and brain metabolism of adenosine and adenosine analogs. J. Pharmacol. Exp. Ther. 268, 14–18 (1994). 10.1016/s0022-3565(25)38458-2

[20]

Isakovic, A. J., Abbott, N. J. & Redzic, Z. B. Brain to blood efflux transport of adenosine: blood–brain barrier studies in the rat. J. Neurochem. 90, 272–286 (2004). 10.1111/j.1471-4159.2004.02439.x

[21]

Couvreur, P. et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6, 2544–2548 (2006). 10.1021/nl061942q

[22]

Reddy, L. H. et al. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J. Pharmacol. Exp. Ther. 325, 484–490 (2008). 10.1124/jpet.107.133751

[23]

Hillaireau, H. et al. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials 34, 4831–4838 (2013). 10.1016/j.biomaterials.2013.03.022

[24]

Bisgaier, C. L., Minton, L. L., Essenburg, A. D., White, A. & Homan, R. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays. J. Lipid Res. 34, 1625–1634 (1993). 10.1016/s0022-2275(20)36955-8

[25]

Kitagawa, H., Mori, A., Shimada, J., Mitsumoto, Y. & Kikuchi, T. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol. Res. 24, 317–323 (2002). 10.1179/016164102101199819

[26]

Tatlisumak, T. et al. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 29, 1952–1958 (1998). 10.1161/01.str.29.9.1952

[27]

Pignataro, G., Simon, R. P. & Boison, D. Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J. Cereb. Blood Flow Metab. 27, 1–5 (2007). 10.1038/sj.jcbfm.9600334

[28]

Von Lubitz, D. K. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 371, 85–102 (1999). 10.1016/s0014-2999(99)00135-1

[29]

Echavarria-Pinto, M. et al. Low coronary microcirculatory resistance associated with profound hypotension during intravenous adenosine infusion: implications for the functional assessment of coronary stenoses. Circ. Cardiovasc. Interv. 7, 35–42 (2014). 10.1161/circinterventions.113.000659

[30]

Go, A. S. et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129, e28–e292 (2014). 10.1161/circulationaha.113.003961

[31]

Yemisci, M. et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nature Med. 15, 1031–1037 (2009). 10.1038/nm.2022

[32]

Hamilton, N. B., Attwell, D. & Hall, C. N. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front. Neuroenerg. 2, 1–14 (2010). 10.3389/fnene.2010.00005

[33]

Li, S. et al. Intracellular ATP concentration contributes to the cytotoxic and cytoprotective effects of adenosine. PLoS ONE 8, e76731 (2013). 10.1371/journal.pone.0076731

[34]

Paterniti, I. et al. Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. J. Neuroinflam. 8, 31 (2011). 10.1186/1742-2094-8-31

[35]

Okonkwo, D. O. et al. A comparison of adenosine A2A agonism and methylprednisolone in attenuating neuronal damage and improving functional outcome after experimental traumatic spinal cord injury in rabbits. J. Neurosurg. Spine 4, 64–70 (2006). 10.3171/spi.2006.4.1.64

[36]

Kwon, B. K., Hillyer, J. & Tetzlaff, W. Translational research in spinal cord injury: a survey of opinion from the SCI community. J. Neurotrauma 27, 21–33 (2010). 10.1089/neu.2009.1048

[37]

Basso, D. M., Beattie, M. S. & Bresnahan, J. C. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp. Neurol. 139, 244–256 (1996). 10.1006/exnr.1996.0098

[38]

Shi, Y. et al. Effective repair of traumatically injured spinal cord by nanoscale block copolymer micelles. Nature Nanotech. 5, 80–87 (2010). 10.1038/nnano.2009.303

[39]

Alavijeh, M. S. & Palmer, A. M. Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds. Neurobiol. Dis. 37, 38–47 (2010). 10.1016/j.nbd.2009.09.025

[40]

Levine, A. S. & Morley, J. E. Effect of intraventricular adenosine on food intake in rats. Pharmacol. Biochem. Behav. 19, 23–26 (1983). 10.1016/0091-3057(83)90305-2

[41]

Portas, C. M., Thakkar, M., Rainnie, D. G., Greene, R. W. & McCarley, R. W. Role of adenosine in behavioral state modulation: a microdialysis study in the freely moving cat. Neuroscience 79, 225–235 (1997). 10.1016/s0306-4522(96)00640-9

[42]

Porkka-Heiskanen, T., Alanko, L., Kalinchuk, A. & Stenberg, D. Adenosine and sleep. Sleep Med. Rev. 6, 321–332 (2002). 10.1053/smrv.2001.0201

[43]

Melani, A., Corti, F., Cellai, L., Giuliana Vannucchi, M. & Pedata, F. Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia. Brain Res. 1551, 59–72 (2014). 10.1016/j.brainres.2014.01.014

[44]

Poller, B. et al. The human brain endothelial cell line hCMEC/D3 as a human blood–brain barrier model for drug transport studies. J. Neurochem. 107, 1358–1368 (2008). 10.1111/j.1471-4159.2008.05730.x

Cited By

227

“No-reflow” phenomenon in acute ischemic stroke

Yang Zhang, Miaowen Jiang · 2023

Journal of Cerebral Blood Flow &amp...

Nanoparticulation of Prodrug into Medicines for Cancer Therapy

Yuezhou Zhang, Huaguang Cui · 2021

Advanced Science

Carbon dot targeting to nitrogen signaling molecules for inhibiting neuronal death

Lufei Ouyang, Xiaoyu Mu · 2020

Journal of Materials Chemistry B

Microthrombus‐Targeting Micelles for Neurovascular Remodeling and Enhanced Microcirculatory Perfusion in Acute Ischemic Stroke

Yifei Lu, Chao Li · 2019

Advanced Materials

In Vivo Biosensing Using Resonance Energy Transfer

Shashi Bhuckory, Joshua C. Kays · 2019

Biosensors

Experimental neuroprotection in ischemic stroke: a concise review

Gary B. Rajah, Yuchuan Ding · 2017

Neurosurgical Focus

Metrics

227

Citations

44

References

Details

Published: Nov 24, 2014
Vol/Issue: 9(12)
Pages: 1054-1062
License: View

Authors

Sinda Lepêtre-Mouelhi

Department of Anatomy, Hacettepe University, Faculty of Medicine;

S

Sébastien Garcia-Argote

G

Grégory Pieters

Université Paris-Saclay; CEA, Département Médicaments et Technologies pour la Santé (DMTS), SCBM

O

Olivier Loreau

Service de Chimie Bio-Organique et Marquage (SCBM), CEA-DRF-JOLIOT-SCBM, Université Paris-Saclay, 91191 Gif sur Yvette, France

B

Bernard Rousseau

Laboratoire de Chimie Physique, UMR CNRS 8000, Université Paris-Sud, 91405 Orsay, France

Department of Neuroscience, Bilkent University , Ankara 06800 ; Department of Molecular Biology and Genetics, Bilkent University , Ankara 06800

P

Patrick Couvreur

Cite This Article

Alice Gaudin, Muge Yemisci, Hakan Eroglu, et al. (2014). Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nature Nanotechnology, 9(12), 1054-1062. https://doi.org/10.1038/nnano.2014.274

Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury

You May Also Like